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http://www.herpesviridae.org/content/5/1/1RESEARCH Open AccessEpstein-Barr virus IL-10 gene expression by a
recombinant murine gammaherpesvirus in vivo
enhances acute pathogenicity but does not
affect latency or reactivation
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Background: Many viral genes affect cytokine function within infected hosts, with interleukin 10 (IL-10) as a
commonly targeted mediator. Epstein-Barr virus (EBV) encodes an IL-10 homologue (vIL-10) expressed during
productive (lytic) infection and induces expression of cellular IL-10 (cIL-10) during latency. This study explored the
role of vIL-10 in a murine gammaherpesvirus (MHV) model of viral infection.
Methods: The EBV vIL-10 gene was inserted into MHV-76, a strain which lacks the ability to induce cIL-10, by
recombination in transfected mouse cells. Mice were infected intranasally with the recombinant, vIL-10-containing
MHV-76 or control virus strains and assayed at various days post infection for lung virus titer, spleen cell number,
percentage of latently infected spleen cells and ability to reactivate virus from spleen cells.
Results: Recombinant murine gammaherpesvirus expressing EBV vIL-10 rose to significantly higher titers in lungs
and promoted an increase in spleen cell number in infected mice in comparison to MHV strains lacking the vIL-10
gene. However, vIL-10 expression did not alter the quantity of latent virus in the spleen or its ability to reactivate.
Conclusions: In this mouse model of gammaherpesvirus infection, EBV vIL-10 appears to influence acute-phase
pathogenicity. Given that EBV and MHV wild-type strains contain other genes that induce cIL-10 expression in
latency (e.g. LMP-1 and M2, respectively), vIL-10 may have evolved to serve the specific role in acute infection of
enlarging the permissive host cell population, perhaps to facilitate initial survival and dissemination of viral-infected
cells.
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Viruses from a range of virus families exert direct influence
on host cytokine responses. Such influence can be medi-
ated through expression of viral homologs of host cyto-
kines or cytokine receptors, or through expression of viral
factors that alter expression of host cytokines [1-3]. Several
herpesviruses such as Epstein-Barr virus (EBV) [4], equid
herpesvirus 2 [5], ovine herpesvirus 2 [6], and primate cy-
tomegaloviruses [7-9] encode a homolog to the IL-10 gene.
Infection of B cells by EBV results in expression of virus-
encoded IL-10 (vIL-10, encoded by the BCRF1 gene) as* Correspondence: glindquester@rhodes.edu
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article, unless otherwise stated.well as induction of the endogenous cellular IL-10 (cIL-10)
gene. vIL10 mRNA is detectable within six hours of EBV
infection in vitro [10] and thus is expressed early in infec-
tion [11]. In fact, EBV virions carry a number of viral
mRNAs including those encoding vIL-10, which may be
translated immediately upon infection [12]. Subsequently,
expression of the cIL-10 gene is induced twenty to forty
hours post-EBV infection [10,13,14] and is upregulated by
the EBV latency-associated LMP-1 and small non-coding
RNAs (EBERs) [15,16]. The differential timing of expres-
sion of these two IL-10 forms may reflect differences in
their respective roles in viral infection.
IL-10 is a highly pleotropic, regulatory cytokine with
differential effects in T-cell populations that generallyntral Ltd. This is an Open Access article distributed under the terms of the
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, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Lindquester et al. Herpesviridae 2014, 5:1 Page 2 of 9
http://www.herpesviridae.org/content/5/1/1reduce inflammation and cytotoxic responses, while favor-
ing a humoral immune response [17]. The EBV vIL-10 [4],
like its cellular counterpart, inhibits cytokine synthesis
[18]. EBV vIL-10 is 84% homologous to human IL-10, with
most divergence occurring at the N terminus [4] resulting
in an altered N-terminal structure [19]. cIL-10 and vIL-10
enhance B-cell viability, whereas only cIL-10 upregulates
MHC II on B cells [20]. vIL-10 also lacks cIL-10’s ability to
stimulate mast cells [21] and to induce proliferation of
mature and immature thymocytes [22]. EBV vIL-10 has
1000-fold lower affinity for the IL-10 receptor, perhaps
explaining its greatly reduced ability to inhibit IL-2 produc-
tion by helper T cells [23]. Thus, the viral and cellular
homologs share many immunosuppressive activities, while
vIL-10 generally lacks cIL-10’s immunostimulatory func-
tions. These differences are attributed primarily to a single
amino acid substitution [24].
In earlier studies involving an EBV mutant in which the
vIL-10-encoding gene was deleted, vIL-10 was concluded
to have no effect on replication, immortalization and estab-
lishment of latency within B cells in vitro, and to have no
effect on tumorigenicity when the resulting EBV-infected B
lymphoblastoid cell lines were injected into SCID mice
[11]. More recent in vitro studies with vIL-10-deficient EBV
virus have demonstrated that vIL-10’s early expression
protects infected B cells by altering the cytokine response,
reducing NK cell killing, and inhibiting CD4+ T cell activity
[12]. In vivo, expression of the vIL-10 gene of the betaher-
pesvirus rhesus cytomegalovirus (RhCMV), significantly
limits innate immune responses to primary infection, which
in turn reduces both T- and B-cell responses [25]. However,
the applicability of the latter study to understanding EBV
vIL-10 function is questionable given the low (27%) hom-
ology of RhCMV vIL-10 with cIL-10 [9] and the high bind-
ing affinity of RhCMV vIL-10 relative to EBV vIL-10 for the
IL-10 receptor [26]. To date, studies probing the nuances
of EBV vIL-10 in gammaherpesvirus infection have not
been presented in an in vivo model of viral pathogenicity.
Murine gammaherpesvirus 68 (MHV-68, γHV68, murid
herpesvirus 4) infection of laboratory mice serves as a tract-
able animal model for gammaherpesvirus pathogenesis
[27]. Upon intranasal (i.n.) inoculation of mice, MHV-68
rapidly establishes an acute, productive infection of alveolar
epithelial cells which is essentially cleared about 10 days
post-infection (p.i.) [28]. As the acute phase resolves, a
syndrome similar to EBV-induced infectious mononucle-
osis ensues. This phase is characterized by splenomegaly
[29], non-antigen-specific B-cell activation [30], and periph-
eral blood lymphocytosis primarily reflecting the expansion
of CD8+ T cells expressing a Vβ4 T-cell receptor [31]. This
syndrome peaks at day 14 p.i. and resolves by about day 21
p.i. Latent virus has been detected in peritoneal macro-
phages [32], splenic macrophages and dendritic cells [33],
and B cells [33-36]. B cells are likely to be the means fortrafficking MHV-68 from the lung to the spleen [37] and
expression of vtRNAs, a marker for latency, has been
localized to the germinal centers in the spleen [38-40].
CD4+ T cells are required for MHV-68-induced spleno-
megaly [29,41], while CD8+ T cells are critical for limiting
productive pulmonary infection and for the resolution of
splenomegaly [35,41-43].
MHV-76, a variant of MHV-68, contains a deletion of
9538 bp within the left end of the unique-sequence domain
of the MHV-68 prototype genome – the region which
includes the MHV-68 genes M1-M4 as well as eight
vtRNA genes [44,45]. In comparison to MHV-68, MHV-76
is cleared more rapidly from the lungs and induces less
pronounced splenomegaly and fewer numbers of latently
infected cells in the spleen, although replication of the
viruses in culture does not differ [44,45]. The M2 gene
encodes a latency-associated protein that serves as a target
for cell-mediated immunity [46]. The M2 protein binds
Vav signaling proteins and promotes cell proliferation and
survival [47]. MHV-68 strains lacking only M2 expression
show the same reduction in latency and reactivation as
MHV-76; however, they do not exhibit MHV-76’s reduction
of splenomegaly [48-50]. While MHV-68 does not carry a
native vIL-10 gene, M2 stimulates cIL-10 expression
[51,52]. It has been proposed that M2’s role in stimulating
cIL-10 and its resulting effects may represent a conserved
gammaherpesvirus strategy that is also represented by the
EBV vIL-10 gene [51], although, as noted above, the timing
of vIL-10 expression differs from that of cIL-10 induction.
Therefore, we sought to determine the effects of vIL-10
expression on viral pathogenesis in a murine gammaher-
pesvirus strain lacking M2 (MHV-76). Here we show that
vIL-10 expression by MHV-76 enhances spleen cell prolif-
eration and viral titers in the lung during acute infection,
but does not affect splenic latency or reactivation of virus
replication from latently infected cells.
Methods
Cell and virus culture
All MHV strains were propagated in NIH-3T3 (ATCC)
cells in DMEM (GIBCO) supplemented with 10% fetal
bovine serum (HyClone), penicillin (100U/ml) and strepto-
mycin (100 μg/ml) (GIBCO) at 37°C in a humidified 5%
CO2 atmosphere essentially as described [28]. Viral titers
were determined in a serial dilution plaque assay by fixing
[10% formalin (Fisher)] and staining [0.1% toluidine blue
(LabChem)] 3–5 days p.i.
Generation of recombinant viruses
Promoter: Pgp150, the MHV-68 late gene promoter for
the M7 gene (expressing gp150), was isolated from
MHV-68 DNA by PCR amplification of a 660 base pair
(bp) fragment that begins 3 bp upstream of the M7 ORF
start codon and extends upstream. The Pgp150 primers
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5′-CAGTAAGCTTGAGGGTTTTATAGCGTCAC-3′) in-
cluded BglII and HindIII restriction enzyme sites at the
upstream and downstream ends, respectively. Pro-
moters were inserted into the BglII and HindIII sites of
the pGL3-Basic (sans promoter) luciferase reporter
plasmid (Promega). Luciferase expression assayed with
the Dual-Luciferase system (Promega) confirmed the
activity of the promoters in NIH-3T3 cells transfected
(FuGene, Roche) with the resulting plasmids.
vIL-10: The vIL-10 gene (encoded by the EBV BCRF1
ORF) was amplified by PCR from EBV (Akata strain)
DNA using primers that generated NcoI and XbaI re-
striction sites at the upstream and downstream ends,
respectively. Primers were 5′-GTGACCATGGAGCGAA
GGTTAGTG-3′ and 5′-AGTGTCTAGATGCACCCAT
CTCCTGCTTC-3′. The amplified product was cloned
into the Pgp150-containing plasmid in place of the
luciferase gene to create the vIL-10 expression cassette.
Positive ELISA (Pierce) confirmed vIL-10 expression
from plasmids in transfected NIH-3T3 cells.
Targeting cassette: Plasmid pBS76LHE (courtesy of James
Stewart) contains an approximately 3-kbp fragment from
the left hand end (LHE) unique sequence of the MHV-76
genome [53] and was modified to generate pBS76LHE-TR
as follows. A portion of a terminal repeat fragment and its
immediately adjacent unique sequence was amplified from
MHV-68 DNA by PCR under conditions favorable for GC
rich sequences (Roche). Primers were 5′-AGGCAGGCAC-
CAACAG-3′ and 5′-CAGCATCAGCCCCGGATCTC-3′.pBSLHE-TR
Expression
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… Promoter
BglII
… TR
PmeI
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BamHIPmeI
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Figure 1 Schematic of approach to generating recombinant viruses. E
insertion of the EBV vIL-10 gene along with the MHV76 gp150 promoter (Pgp
cassette between the MHV76 terminal repeat segment (TR) and unique seque
vector (see Methods). The targeting cassette was generated for this study wit
the asymmetric regeneration of the BamHI site during insertion (X = no restric
into NIH-3T3 cells for recombination. Once isolated, recombinant viral DNA w
NIH-3T3 cells to generate revertant viruses.This fragment, designated TR, represents terminal re-
peat sequences immediately to the left (in the prototype
orientation) of the LHE fragment in MHV-76. TR was
inserted next to the LHE fragment in pBS76LHE to
generate pBSLHE-TR; a BamHI site separates TR from
LHE. Furthermore, PmeI restriction enzyme sites were
inserted on either side of the TR-LHE sequence to be
able to liberate the TR-LHE targeting cassette. Next,
the vIL10 expression cassette was liberated from its
plasmid as a fragment with a BglII restriction site on
the upstream end and a BamHI restriction site on the
downstream end. This fragment was inserted into the
BamHI site of pBS76LHE-TR and restriction enzyme
analysis revealed clones containing the expression cas-
sette in either orientation bounded by the TR and LHE
components. Figure 1 shows a general schematic of
construction of the targeting cassette.
Recombination and purification: NIH-3T3 cells grown
in 6-well plates were co-transfected using FuGene (Roche)
with MHV-76 DNA (1 μg, isolated essentially as described
[54]) and targeting cassette (2–3 μg of PmeI-digested
targeting-construct plasmid). Following the development
of plaques, cultures were harvested and subjected to three
rapid freeze/thaw cycles to release cell-associated virus.
Stocks were serially diluted to infect NIH-3 T3 cells in 96-
well plates. DNA was isolated from wells developing single
plaques by QiaAmp (Qiagen) and screened by PCR for the
presence of the vIL-10 gene. This limiting-dilution screen-
ing was repeated for five or six rounds until all plaques
were PCR positive for vIL-10. Positive ELISA (Pierce)… in pGL3
BamHI
vIL-10
… in pBSLHE
PmeIBamHI
p150.vIL-10L
PmeIX
Pgp150 LHE
xpression cassettes were created in the pGL3-Basic vector (Promega) by
150). Targeting cassettes were created by insertion of the expression
nces of the left hand end (LHE, prototype orientation) in the pBSLHE-TR
h transcription from Pgp150 in the leftward direction, as determined by
tion site). The targeting cassette and MHV76 DNA were co-transfected
as co-transfected along with the TR-LHE segment from pBSLHE-TR into
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infected NIH-3T3 cells. Revertant control viruses were gen-
erated using the preceding procedures by co-transfection of
cell cultures with recombinant virus DNA and the TR-LHE
fragment lacking an expression cassette insert. All recom-
binant DNA work was conducted under protocols ap-
proved by the Institutional Biosafety Committee following
US federal guidelines.
In vitro growth curves
NIH-3T3 cell cultures (70-80% confluent) were infected
at a multiplicity of infection (MOI) of 5. Virus was
allowed to adsorb for one hour at 37°C, and cells were
washed three times with fresh medium to remove
unbound virus. Samples were taken at time zero and
appropriate time points thereafter by scraping the cells
and collecting by aspiration. Cells were freeze-thawed
three times to release cell-associated virus, and viral
titers were determined by plaque assay.
Inoculation and sampling of mice
Four- to six-week-old male BALB/c mice (Jackson
Laboratories) under light anesthesia (isoflurane, 1.5-2.5%,
by inhalation) were inoculated i.n. with 2 × 105 pfu virus
[45]. At various times p.i., mice were euthanized by CO2
asphyxiation followed by cervical dislocation. Lungs were
removed and snap frozen. Spleens were removed and held
briefly in tissue culture medium. After spleens were
weighed, they were homogenized by passage through a
mesh screen, and red blood cells were lysed in Red Blood
Cell Lysing Buffer (Sigma-Aldrich). Leukocytes were
recovered from the pellet following centrifugation by
resuspension in tissue culture medium, and aliquots of
cells were counted to calculate number of leukocytes per
spleen. All animal work was conducted under protocols
approved by the Institutional Animal Care and Use
Committee following US federal guidelines.
Quantification of lytic virus
Spleens and lungs were harvested from euthanized mice
various days p.i. and homogenized (Mini-BeadBeater-8,
as described [36]). Supernatants were freeze-thawed and
clarified by centrifugation. Virus titers were determined
by plaque assay of serial dilutions on NIH-3T3 cells.
Quantification of latent virus
Viral DNA was detected using a limiting-dilution, nested
PCR assay for the MHV-68 ORF50 gene with single-copy
sensitivity essentially as described [32,50].
Reactivation assay
The limiting-dilution assay as described by Weck [36]
was used to assess reactivation from latently infected
spleen cells. Briefly, mouse embryonic fibroblast (MEF)cells (ATCC), were plated in 96-well culture plates and
inoculated with limiting-dilutions of splenic leukocytes or
splenic-cell lysates, and results were analyzed after 14–21
days with subtraction of any detectable lytic virus present
in the lysate. Statistical analysis of all experiments was
conducted using GraphPad Prism software.
Results
Construction of recombinant MHV-76 and expression of
vIL-10
For expression of the EBV vIL-10 gene in MHV-76, we
utilized the MHV-68 M7 late-gene promoter which allows
transcription of the gp150 protein. A 660-bp fragment
from upstream of the gp150 start codon was amplified by
PCR and inserted directly upstream of the luciferase gene
in Promega’s pGL3-basic vector. The promoter was suc-
cessful in driving expression of luciferase when the plas-
mid was transfected into NIH-3T3 cells with or without
MHV-76 viral infection (data not shown). The luciferase
coding sequences were then replaced with the coding
sequences for EBV vIL-10. The new constructs were
successful in expressing vIL-10 in NIH-3T3 cells with
similar expression levels in uninfected cells and in cells
infected with MHV-76 (Figure 2).
The gp150-promoter/vIL-10 cassette was then inserted
between the terminal repeat and the unique sequences of
the left hand end of the cloned MHV-76 DNA to create
the targeting cassette (Figure 1). The targeting cassette
was liberated from its plasmid by restriction enzyme
digestion and co-transfected with MHV-76 DNA into
NIH-3T3 cells to allow for recombination within the TR
and LHE sequences, effectively inserting the vIL-10 gene
into the MHV-76 genome. Putative recombinant viruses
(designated 76.vIL10) were screened by PCR upon
multiple rounds of limiting-dilution infections in vitro
until a purified culture of vIL-10 PCR-positive virus was
obtained. Expression of vIL-10 by recombinant viruses
was confirmed by ELISA, which demonstrated a mean
concentration of vIL-10 three days p.i. in cell culture
supernatant of 11 ng/ml (standard deviation = 5.5 ng/ml;
three trials with duplicate samples per trial). Finally,
recombinant virus was co-transfected with a fragment
containing the TR-LHE contiguous sequence in order to
create a revertant virus strain (designated 76.rev). Insertion
and integrity of the promoter and gene sequences were
confirmed by DNA sequence analysis and MHV-76, 76.
vIL10, 76.rev, and MHV-68 virus strains all were shown to
have very similar in vitro growth rates (Figure 3).
vIL-10 enhances acute viral titers in lungs
Previous studies have shown that MHV-76 titer in
infected-mouse lungs peaks at day 4 p.i., while MHV-68
titer peaks significantly higher and at day 6 p.i. [45]. In
these experiments (Figure 4), viral titers in lungs at day
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Figure 2 vIL-10 is expressed in transfected cells. NIH-3T3 cells
were transfected with plasmid containing the Pgp150.vIL10 expression
cassette or control plasmid (pGL3-Promoter) and infected or not with
MHV-76 at a MOI of 1. After 24, 36, and 48 hours, supernatant was
tested for the presence of vIL-10 by ELISA. Data points represent the
averages of two readings of each sample in duplicate experiments.
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Figure 4 vIL10 increases acute-phase titer in lungs. Four- to
six-week-old BALB/c mice were infected i.n. with 2x105 pfu of virus in 40
milliliters. Viral titers from homogenized left lungs were determined on
NIH-3T3 cells. Data represent three independent experiments with titers
performed in duplicate. Pairwise statistical analysis shows no significant
differences between titers of MHV68 or 76 or between either of these
viruses and the recombinants. Statistical significance by unpaired t-test
with Welch’s correction is indicated (*): 76.vIL10 vs MHV-76 (P= 0.0025),
76.vIL10 vs 76.rev (P< 0.0001), MHV-68 vs 76.rev (P= 0.0076).
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76.vIL10 than either MHV-76 (P = 0.0025) or the re-
vertant control strain, 76.rev (P < 0.0001). These
results demonstrate that vIL-10 allows enhanced
acute viral titers in lungs. Furthermore, no significant
difference was seen in titers at this time point for
MHV-68 versus 76.vIL10. While MHV-68 titers were
significantly higher than those of 76.rev (P = 0.0076),
the marginally higher mean titer of MHV-68 versus
MHV-76 was not significant.
vIL-10 promotes an increase in spleen cell number
The development of splenomegaly, a characteristic of MHV
acute phase infection that normally peaks from day 10–14
p.i., was assessed by determining the total number of leuco-
cytes in infected-mouse spleens. Splenocyte counts were
determined at days 10, 14, and 21 p.i. (Figure 5). As
expected [45], MHV-68 compared to MHV-76 resulted in
a significant increase in number of splenocytes throughout
the measured course of infection, with peak expansion
of the population at day 14 (day 10, P = 0.0106; day 14,
P < 0.0001; day 21, P = 0.0005). Splenocyte counts
peaked at day 10 p.i. in mice infected with either thevIL-10-containing strain 76.vIL10, or its parent strain,
MHV-76. However, at day 14 p.i., 76.IL10-infected
mice had a significantly greater number of splenocytes
than MHV-76-infected mice (P < 0.0001). Thus, while
expression of vIL-10 did not appear to affect the
Figure 6 vIL10 does not affect the quantity of latent virus.
Spleen cells underwent three-fold dilutions with 12 duplicate wells per
dilution. Viral DNA was detected by nested PCR to orf50. Curve-fit lines
represent results of nonlinear regression analysis. Data points represent
the mean of two independent experiments with spleens pooled from
five mice per experiment. Results indicate no difference between
MHV-76 and recombinants with or without vIL10.
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vIL-10 does not alter the quantity of latent virus in spleen
cells or its ability to reactivate
The presence of viral genomes in splenocytes early in
latency was assayed by limiting-dilution PCR. Previous
studies have shown a defect in latency for MHV-76 as
compared to MHV-68 following i.n. inoculation [44,45].
While Figure 6 does not exhibit a significant difference in
PCR-positive cells for the sample size and dilutions tested,
MHV-68 trends toward a higher number of positive cells,
and MHV-76 and 76.vIL10 track together. Importantly,
the expected differences in reactivation between MHV-68
and MHV-76 [44,45] are observed in Figure 7. Data
indicate no significant difference in reactivation of MHV-
76 with or without vIL-10.
Discussion
These results provide the first evidence of vIL-10’s role
in gammaherpesvirus infection in an in vivo model of
viral pathogenicity. vIL-10 expression in MHV-76-
infected mice increases acute-phase pathogenicity, but
does not increase the percentage of latently infected
splenocytes or the level of reactivation of latent virus. In
accordance with these findings, in EBV, in which vIL-10Figure 5 vIL10 increases spleen cell count at day 14. Mice were
infected as indicated in Figure 4. Data represent four independent
experiments with five mice per group. Spleens were harvested on
days 10, 14, and 21 p.i. Spleens of five mice were pooled and
disrupted, and spleen cells were counted. Spleen-cell-count data for
Day 0 represent the average of five spleens from uninfected mice.
Bars represent standard error of the mean. Statistical significance by
unpaired t-test with Welch’s correction is indicated (*): MHV-68 vs
MHV-76 (day 10, P = 0.0106; day 14, P < 0.0001; day 21, P = 0.0005)
and 76.IL10 vs MHV-76 (day 14, P < 0.0001).is expressed in its native environment, several studies
have associated the gene’s expression with the acute
phase of infection [13,21,55].
Nevertheless, IL-10 and its ability to drive B cell prolifer-
ation and differentiation into plasma cells are considered
significant factors in the process of gammaherpesvirus
reactivation from latency. The MHV-68 M2 gene product
stimulates cIL-10 expression and subsequent B cell prolif-
eration and differentiation [51]. The M2 protein exerts this
effect by activating the NFAT signal transduction pathway
which induces expression of interferon regulatory factor-4
(IRF-4), in turn inducing cIL-10 expression [52]. cIL-10
expression is also induced in EBV-infected cells by latency-
associated LMP-1 and small non-coding RNAs (EBERs)
[15,16], and in Kaposi’s sarcoma-associated herpesvirus
(KSHV) by viral-encoded miRNA [56]. Whether vIL-10
plays a role in EBV infection in the human similar to that
of cIL-10 induction by MHV-68’s M2 protein in the mouse
remains to be shown. However, with EBV’s other means of
inducing cIL-10 during latency, it is possible that EBV
expression of vIL-10 serves a different function. Results
presented in this paper suggest that vIL-10’s role may be in
enhancing infection during the acute (lytic) phase.
Early expression of vIL-10 homologues by herpesviruses
appears to increase the local pool of host cells permissive
for infection, thus increasing the chance for trafficking of
infected cells to other sites. For example, human cyto-
megalovirus (HCMV) and RhCMV encode IL-10 homo-
logs that induce the differentiation of macrophages [25], a
cell type shown to be permissive for CMV infection
[57,58]. Our results have shown that EBV vIL-10 expres-
sion by MHV-76 increases splenomegaly, where MHV-
induced splenomegaly results, in part, from an increase in
1 2 3 4 5
0
20
40
60
80
100
Log10 cells per well
%
w
e
lls
w
ith
CP
E
1 2 3 4 5
0
20
40
60
80
100
Log10 cells per well
%
w
e
lls
w
ith
CP
E
MHV-68
76.vIL10
MHV-76
76.rev
1 2 3 4 5
0
20
40
60
80
100
Log10 cells per well
%
w
el
ls
w
ith
C P
E
Day 10 p.i.
Day 14 p.i. Day 21 p.i.
Figure 7 vIL10 does not affect the quantity of reactivating virus. Spleen cells were plated atop MEF cells in dilutions across 96-well plates as
indicated on the x-axes with 16 duplicate wells per dilution. Wells were scored for CPE on days 10, 14 and 21. Curve-fit lines represent results of
nonlinear regression analysis. Data points represent the mean of two independent experiments with spleens pooled from five mice per experiment.
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trafficking MHV-68 from the lung epithelium to the
spleen [37].
In addition to increasing the pool of host cells to expand
and disseminate primary infection, early expression of
viral IL-10 homologues reduces virus-specific effector
responses, helping to ensure the survival of infected cells
into the latent phase. Such inhibition can occur upstream
of effector cell activation by inhibiting innate responses
critical to the transition to adaptive immunity. RhCMV
IL-10 reduces dendritic cell populations in draining lymph
nodes, resulting in a lower frequency of virus-specific T
cells [25]. EBV vIL-10 modulates cytokine responses [12],
reduces MHC I expression [59], avoids increasing MHC II
expression [20], and inhibits monocytes [60]. vIL-10 can
also inhibit effector cell responses directly. For example,
vIL-10 limits NK cell killing of infected B cells and inhibits
CD4+ T cell activity [12]. Studies are planned that will
assess effector responses in mice infected with 76.vIL-10.
The timing and level of expression of vIL-10 are likely
to relate significantly to vIL-10’s influence on pathogen-
icity. Expression of vIL-10 by the recombinant virus
used in this study was quantified by an ELISA that
distinguished vIL-10 from any cIL-10 that might have
been produced by host cells. However, it is difficult to
know how this level of expression compares to expres-
sion of vIL-10 in EBV-infected cells. Published studieshave reported vIL-10 concentrations in functional units
[14] or fluorescence units [61] rather than in units of mass.
Furthermore, the difference in culture conditions for
recombinant MHV and EBV would make such compari-
sons difficult to interpret. Finally, it would be of interest to
determine if recombinant viruses package vIL-10 mRNA
in the virion and express the product immediately upon
infection as has been shown for EBV [12] as well as to
ascertain the kinetics of expression of vIL-10 by recombin-
ant MHV in the host animal.
Details are emerging to clarify our understanding of viral
modulation of immune responses via cIL-10 and vIL-10.
Such understanding may expand our ability to intervene in
diseases such as EBV-associated lymphoproliferative dis-
ease [62]. Several studies have exploited the immunomod-
ulatory properties of EBV vIL-10 for increasing the survival
of allografts [63-70]. The establishment of this model
murine gammaherpesvirus expressing vIL-10 may contrib-
ute further to such work.
Conclusions
In this mouse model of gammaherpesvirus infection, EBV
vIL-10 appears to influence the acute-phase pathogenicity
by increasing the viral titers in lungs and increasing the
number of spleen cells, resulting in enhanced splenomegaly.
However, following the establishment of latency, vIL-10
expressing strains showed no difference in the percentage
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reactivate. Given that EBV and MHV contain other genes
that induce cIL-10 expression in latency (e.g. LMP-1 and
M2, respectively), vIL-10 may have evolved to serve the
specific role in acute infection of enlarging the permissive
host cell population, perhaps to facilitate dissemination and
initial survival of viral-infected cells.
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